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Neuroscience Research 61 (2008) 429–432AbstractAdministration of nitroglycerol in a migraine model results in an increased number of c-fos-expressing secondary sensory neurons in the caudal
trigeminal nucleus. Since synapses between first- and second-order trigeminal neurons are mediated by excitatory amino acids, NMDA receptors
are inhibited by kynurenic acid, though this crosses the blood–brain barrier only poorly. Systemic treatment of rats with SZR-72, a newly
synthetized kynurenic acid analog, diminished the nitroglycerol-induced increase of c-fos immunoreactivity in the brain stem highly significantly,
while treatment with kynurenic acid resulted in a significantly smaller decrease, proving that SZR-72 is much more effective than kynurenic acid.
# 2008 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
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tion-induced calcium entry into the cell (Morgan and Curran,
1986), the immunohistochemical demonstration of c-fos
protein is widely used as a marker for neuronal activity
(Centini and Pompeiano, 2007; Guo et al., 2007). Nitroglycerol
is known to induce headache and increase the expression of c-
fos in the nuclei of second-order sensory neurons in the caudal
trigeminal nucleus (Tassorelli et al., 2005).
Kynurenine, derived from the tryptophan metabolism, can
be converted by the enzyme kynurenine aminotransferase to
kynurenic acid (KYNA). Synaptic transmission between first-
and second-order trigeminal sensory neurons is mediated by a
glutamatergic mechanism (Goadsby and Classey, 2000).
Accordingly, it is reasonable to assume that KYNA, one of
the few known endogenous N-methyl-D-aspartate (NMDA)
inhibitors, would inhibit the synaptic activity of aminacidergic* Corresponding author. Tel.: +36 62 545915; fax: +36 62 545597.
E-mail address: knyihar@nepsy.szote.u-szeged.hu (E. Knyihar-Csillik).
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doi:10.1016/j.neures.2008.04.009synapses such as those at the central terminals of primary
trigeminal sensory neurons. KYNA is known to act as an
antagonist at the glutamate-binding site of the NMDA receptor
(Forrest et al., 2005; Schwarcz and Pelliciari, 2002; Stone and
Darlington, 2002). Thus, an increased brain level of KYNA can
be a therapeutic factor. Although KYNA crosses the BBB only
poorly or not at all (Fukui et al., 1991), systemic administration
of the compound glucosamine-KYNA leads to an increased
KYNA concentration in the brain (Robotka et al., 2005).
Another possibility is to combine kynurenine, the precursor of
KYNA, with probenecid, which markedly inhibits pentylene-
tetrazonium-induced seizures (Vecsei et al., 1992; Nemeth
et al., 2004). In recent studies (Knyihar-Csillik et al., 2007),
systemic treatment with kynurenine and probenecid signifi-
cantly diminished the nitroglycerol-induced increase of c-fos
immunoreactivity in the brain stem.
Preliminary mass spectrographic studies suggested that
SZR-72, a novel kynurenate analog, synthetized by us (patent
pending) appears in the cerebrospinal fluid after i.v. admin-
istration. On these premises, the hypothesis was tested ofscience Society. All rights reserved.
Table 1
Distribution of c-fos-immunoreactive cells at different levels in control (a), in
nitroglycerol-treated (b), kynurenic acid + nitroglycerol-treated (c) and SZR-
72 + nitroglycerol-treated animals (d)
Obex Middle CVn Lower CVn C1 Average
a 85  3 84  5 92  6 98  2 90  4
b 562  9 498  8 524  17 535  14 530  12
c 234  10 241  11 251  14 233  17 240  13
d 152  8 139  9 168  18 145  13 150  12
Values are expressed as means  S.E. Significances of differences between a
and b, c and d, b and c, b and d, and c and a are p < 0.001, whereas the
significance of the difference between c and d is p < 0.01.
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the neuronal activity of second-order sensory neurons in the
caudal trigeminal nucleus more effectively than KYNA.
Investigations were performed on 24 young adult male
albino rats (Rattus norvegicus albus) of theWistar strain, with a
body weight of 200–250 g. The care of the animals complied
with the guidelines of the Hungarian Ministry of Welfare;
experiments were carried out in accordance with the European
Communities Council Directive (24 November 1986; 86/609/
EEC) and the Guidelines for Ethics in Animal Experiments,
Albert Szent-Gyorgyi Clinical Center, University of Szeged.
The animals were divided into four groups, each group
consisting of 6 rats. Group I was treated with isotonic saline.
Group II was treated with nitroglycerol (NitroPOHL, Pohl-
Boskamp, Hohenlockstedt, Germany); 10 mg/kg i.p.; 3-h
follow-up. Group III was treated with KYNA (4-hydroxyquino-
line-2-carboxylic acid; Sigma–Aldrich St. Louis, MO 63178,
USA; 1 mmol/kg i.p.; 2-h follow-up), followed by nitroglycerol
(NitroPOHL; 10 mg/kg i.p.; 3-h follow-up. Group IV was
treated with SZR-72, 1 mmol/kg i.p. (2-h follow-up), followed
by nitroglycerol (NitroPOHL; 10 mg/kg i.p.; 3-h. follow-up).
Under chloral hydrate anesthesia (i.p. 4%, 1 ml/100 g body
weight), the rats were subjected to transcardial fixation with
500 ml cold 4% paraformaldehyde, preceded by a brief flush of
125 ml 0.1-M cold phosphate-buffered saline, pH 7.4. After
perfusion, the medulla was dissected and post-fixed in the same
fixative overnight.
Immunohistochemical localization of c-fos was performed
in cross-sections of the medulla and in the two uppermost
cervical segments of the spinal cord (C1 and C2). The spinal
trigeminal nucleus was regarded as commencing at the bregma
10 mm (interaural 1 mm) level, and extending until the
level of emergence of the first cervical nerve at bregma
17 mm (interaural 8 mm). After cryoprotection, 30 mm
serial sections were incubated at 4 8C overnight with the
polyclonal primary antibody for c-fos protein raised in rabbit
(Santa Cruz, CA, USA) in a 1:1000 dilution in PBS with 0.3%
Triton X-100 and 2% normal goat serum (Vector, Burlingame,
CA, USA). This was followed by a 90-min incubation in
biotinylated anti-rabbit secondary antibody (Vector) at room
temperature on a shaker plate. The further procedure followed
the avidin–biotin technique; visualization of the reaction
product in the c-fos-expressing cells was performed with the
nickel-DAB technique. Sections were dehydrated in graded
ethanol, cleared in xylene and coverslipped with Permount
(Fisher, New Jersey, USA). The specificity of the immunohis-
tochemical reaction was assessed by means of omission of the
primary antiserum, or the use of normal rabbit serum instead of
anti-c-fos antiserum, or treatment via the avidin–biotin
complex method, from which one of the steps had been
omitted. None of these specimens displayed any reaction.
The number of c-fos-immunoreactive neurons was deter-
mined in a blinded manner in the right caudal trigeminal
nucleus (CVn) in each group. Uninterrupted serial sections, 30-
mm thick, were obtained from each animal; the number of
sections was 83–87. The c-fos-immunoreactive cells were
counted semi-automatically with a Nikon Eclipse 600microscope, equipped with a SPOT RT Slider digital camera
(166 dpi  1200 dpi in 8 bits), using the Image Pro Plus v4.5
morphometry software (Media Cybernetics, Silver Spring, MD,
USA). Following background subtraction, the area of interest
was outlined manually; the threshold was determined so that all
labeled nuclei could be recognized; cell counts were then
normalized to 1 mm2. Measurements were performed at four
different levels: (i) at the obex; (ii) at the middle of the CVn;
(iii) at the lower part of the CVn; and (iv) at the site of
emergence of the first cervical nerve. The number of c-fos-
immunoreactive cells was averaged from their numbers in 10
sections at each level. These were summed and extrapolated
over the entire extent (‘‘length’’) of the nucleus (Table 1).
Differences between the numbers of c-fos-immunoreactive
nuclei were determined statistically ( p-value set at 0.05 for
significance), using the ANOVA post hoc Tukey test.
It was found that in Group I animals, c-fos immunoreactivity
was present in a restricted number of second-order sensory cells
in the caudal trigeminal nucleus (CVn, Fig. 1a). Our analysis
indicated that the number of c-fos-immunoreactive cells in the
CVn under normal conditions was 90  4/mm2 (Fig. 2, column
a). Administration of nitroglycerol (10 mg/kg) resulted in a
tremendous increase in the number of c-fos-immunoreactive
neurons (Fig. 1b), to 530  32 mm2 (Fig. 2, column b).
KYNA, 1 mmol/kg, followed by nitroglycerol, induced a
significant decrease in the number of c-fos-expressing cells, to
240  23 mm2 (Fig. 1c and Fig. 2, column c). With a double
dose of KYNA, we observed the same results (data not shown).
However, when nitroglycerol administration was preceded by
SZR-72 treatment (1 mmol/kg), the number of c-fos-immunor-
eactive neurons was decreased to a significantly lower level,
151  12 mm2 (Fig. 1d and Fig. 2, column d).
Statistical analysis demonstrated that the differences
between saline-treated animals (Group I), nitroglycerol-treated
samples (Group II) and the samples treated with kynurenic acid
followed by nitroglycerol (Group III), were significant
( p < 0.001), whereas the difference between saline-treated
animals (Group I) and the samples treated with SZR-72
followed by nitroglycerol (Group IV) was not. The numbers of
c-fos-immunoreactive cells in the caudal trigeminal nucleus in
the four experimental groups are illustrated in Fig. 2.
This first immunohistochemical study with the very
effective, new KYNA analog SZR-72, which inhibits the
nitroglycerol induction of increased c-fos activity in the caudal
Fig. 1. (a) In a control section, only sporadic neuronal nuclei exerted c-fos immunoreactivity in the caudal trigeminal nucleus. (b) Two hours after nitroglycerol
treatment, the number of c-fos-immunoreactive neuronal nuclei (arrow) was markedly increased in the caudal trigeminal nucleus. (c) Nitroglycerol treatment 2 h
following KYNA; because of the slight decreasing effect of KYNA, the number of c-fos-immunoreactive nerve cell nuclei was less than after nitroglycerol alone, but
still significantly more than in the control samples. (d) Nitroglycerol treatment 2 h following SZR-72; the number of c-fos-immunoreactive nerve cell nuclei (arrow)
was not significantly more than in the untreated control samples.
E. Knyihar-Csillik et al. / Neuroscience Research 61 (2008) 429–432 431trigeminal nucleus, supports the results of earlier studies insofar
as the number of c-fos-immunoreactive neurons in the caudal
trigeminal nucleus is increased significantly in consequence of
nitroglycerol treatment (Bullitt, 1990; Hunt et al., 1987;
Menetrey et al., 1989; Mitsikostas and Sanchez del Rio, 2001).
The mitigation by NMDA receptor antagonists of increased c-Fig. 2. Numbers of c-fos-immunoreactive nuclei in laminae I and II of the
caudal trigeminal nucleus and in C1. *p < 0.05, **p < 0.001. Column a: saline-
treated control. Column b: nitroglycerol (NitroPOHL, NP) treatment resulted in
a tremendously increased number of c-fos-immunoreactive neurons. Column c:
KYNA treatment followed by nitroglycerol (NitroPOHL, NP) resulted in a
significant decrease in the number of c-fos-immunoreactive neurons, as com-
pared with the samples treated with nitroglycerol (NitroPOHL, NP) alone.
Column d: effect of nitroglycerol (NitroPOHL, NP) preceeded by a 2-h SZR-72
pretreatment. The increase in the number of c-fos-immunoreactive neurons was
significantly less than in the kynurenic acid-pretreated samples.fos immunoreactivity has been reported by a number of authors
in migraine models (Mitsikostas et al., 1998; Classey et al.,
2001; Filla et al., 2002).
In summary, the pretreatment of experimental animals
with the KYNA analog SZR-72 significantly mitigated the
nitroglycerol-induced increase in the number of c-fos-
immunoreactive nerve cells in the caudal trigeminal nucleus.
Thus, it appears that SZR-72 treatment moderates the
propagation of noxious stimuli in the brain stem, through the
effective inhibition of NMDA receptors. The results of
this migraine model raise the possibility of the use of SZR-
72 or related compounds in the therapy of migraine
headache.
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